The co-founder of Google DeepMind just raised $2.1 billion to, in his own words, solve all disease.
His name is Sir Demis Hassabis. The company is Isomorphic Labs, a DeepMind spinout that uses AI to design drugs. The pitch is simple and enormous: take a drug discovery process that costs around $2.6 billion and runs 10 to 15 years per medicine, and compress it into a fraction of that.
Every outlet led with the $2.1 billion. I want to talk about the part they skipped, because it is the part that actually matters.
First, the receipts, because they are real
This is not a hype founder with a deck. Hassabis won the 2024 Nobel Prize in Chemistry. He is the mind behind AlphaFold, the AI that cracked protein folding in months, after the field had spent 50 years stuck on it.
So when he raised $2.1 billion in a Series B led by Thrive Capital, with Alphabet, GV and sovereign wealth funds from Abu Dhabi, Singapore and the UK, the market was not betting on a promise. It was betting on a track record.
Why three pharma logos matter more than the $2.1 billion
Isomorphic has signed Eli Lilly, Novartis and Johnson & Johnson, including a Lilly deal worth up to $1.7 billion in milestones. Those names matter more than the money, and here is why.
In AI, data is the moat. And healthcare data is the hardest data to get in any industry. Decades of proprietary drug trials, molecular libraries and patient outcomes, all locked behind institutional walls, privacy law and competitive secrecy.
Hassabis did not just raise $2.1 billion. He secured access to some of the most protected datasets in the world. That is the real moat.
The second moat nobody is talking about
The drug industry is one of the most regulated on earth. FDA approval, clinical trials, compliance at every single stage. Most AI companies cannot navigate that. They are not built for it.
Isomorphic is building a repeatable, scalable process to get drugs through that system. And every drug they push through makes the next one easier. That is a structural advantage that compounds.
It is also why the incumbents are partnering instead of competing. Lilly, Novartis and J&J have spent decades learning the regulatory process. They are not partnering with Isomorphic because they cannot build AI. They are partnering because they cannot rebuild the entire discovery infrastructure fast enough to keep up. And they know it.
This is why healthcare is the hottest pitch in venture
The maths is brutal and obvious. Drug discovery costs around $2.6 billion per molecule and takes more than a decade. AI is the first tool that can credibly claim to attack all of that at once. That makes it, full stop, one of the most compelling stories in venture right now.
And that is exactly why you have to be careful
Demis is the most legitimate version of a pattern that is now everywhere. Pedigree founder. Proven track record. An AI wrapper on a big, fear-based problem. A billion-dollar valuation.
The difference with Demis is the receipts. The Nobel. AlphaFold. Data partnerships nobody else can get. He earned the $2.1 billion before he asked for it.
Most people running the same playbook have not. The market right now rewards the formula whether or not the receipts are there. So the hard job, for founders and investors alike, is to separate the builders from the pitch.
He earned the $2.1 billion before he asked for it.
Demis passes that test cleanly. The next ten founders who borrow his exact pitch probably will not. Knowing the difference is the whole game.